Healthcare / Diagnostics & ResearchASX
$0.34
-0.00 (-1.47%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-6.5M · quality 72.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$47M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-32.8%
↓Gross Margin
84.9%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+4.6%
FCF CAGR
—
FCF margin
-840.4%
FCF / Net income
0.69x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $535118.0 · net income $-6.6M · FCF $-4.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $535118.00 | $535118.00 | $398193.00 | $276745.00 | $468096.00 |
| Net Income | $-6.6M | $-6.6M | $-9.0M | $-18.2M | $-12.4M |
| EBITDA | $-6.6M | $-6.6M | $-9.3M | $-7.0M | $-6.1M |
| EPS | -0.07 | -0.07 | -0.10 | -0.07 | — |
| Gross Margin | 84.9% | 84.9% | 88.8% | 79.6% | 86.3% |
| Operating Margin | -1464.6% | -1464.6% | -2630.9% | -3252.0% | -1504.0% |
| Net Margin | -1224.8% | -1224.8% | -2252.5% | -6575.0% | -2642.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.04 | 0.04 | 0.05 |
| Current Ratio | 7.56 | 7.56 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-4.5M | $-4.5M | $-7.3M | $-6.5M | $-6.0M |
| Returns | |||||
| ROE | -32.8% | -32.8% | -45.7% | -64.3% | -44.4% |
| Valuation | |||||
| P/B | 1.55 | 1.55 | 4.18 | 1.67 | 5.42 |
| Growth & Yield | |||||
| Revenue Growth | 34.4% | 34.4% | 43.9% | -40.9% | — |
| EPS Growth | 27.3% | 27.3% | -36.0% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.10 → -0.07
Residual
-23.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.